ArticleLife (Basel, Switzerland)2026
Effects of Olive Leaf Extract on Anxiety Symptoms and Metainflammation in Women with Excess Weight: A Randomized Double-Blind Placebo-Controlled Pilot Trial.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Anxiety symptomatology and excess weight are associated with chronic low-grade inflammation. Olive leaf extract (OLE) contains polyphenols with antioxidant and anti-inflammatory properties that have shown anxiolytic-like effects in experimental models; however, evidence in humans remains limited. This randomized double-blind placebo-controlled pilot trial evaluated the effects of OLE supplementation on anxiety symptomatology, inflammatory markers, and metabolic parameters in women with excess weight and mild to moderate anxiety symptoms. Participants received OLE (750 mg/day) or placebo for 12 weeks. Anxiety symptomatology was assessed using HAM-A, BAI, and STAI, while inflammatory and metabolic parameters were evaluated at baseline and post-intervention. Since the expected sample size was not achieved, our results are preliminary. No effect was observed from OLE supplementation. However, some differences within groups can direct future researchers interested in evaluating these parameters. OLE supplementation correlated with a particular reduction phenotype in anxious symptomatology (HAM-A, BAI and STAI-Trait) with inflammatory (hs-CRP) and metabolic parameters (c-HDL) that may open the possibility of an anti-inflammatory effect. In contrast, the observations in the Pb group seemed more associated with a pro-inflammatory state and a placebo effect related to somatic symptoms of anxiety. These preliminary observations need to be confirmed with larger randomized clinical trials that may help clarify these results and the possible underlying mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.